SCHEMBL29238233

SCHEMBL29238233

COCCOc1cc2ncnc(-c3ccc(NC(=O)C(C)(N)c4ccc(F)cc4)cc3)c2cc1OCCOC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 3/20 0.50
▸ KIT P10721 5/20 0.48
▸ RAF1 P04049 4/20 0.44
▸ BRAF P15056 4/20 0.44
▸ AURKA O14965 1/20 0.43
▸ KDR P35968 3/20 0.43
▸ HDAC3 O15379 2/20 0.43
▸ HDAC4 P56524 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ HDAC7 Q8WUI4 2/20 0.43
▸ HDAC2 Q92769 2/20 0.43
▸ HDAC10 Q969S8 2/20 0.43
▸ HDAC11 Q96DB2 2/20 0.43
▸ HDAC8 Q9BY41 2/20 0.43
▸ HDAC6 Q9UBN7 2/20 0.43
▸ HDAC9 Q9UKV0 2/20 0.43
▸ HDAC5 Q9UQL6 2/20 0.43
▸ MET P08581 2/20 0.43
▸ AURKB Q96GD4 1/20 0.42
▸ IRAK4 Q9NWZ3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26098635 0.87 MET (0.46) PDGFRBKITRAF1BRAFKDR
SCHEMBL26102887 0.86 EGFR (0.53) PDGFRBKITRAF1BRAFAURKA
SCHEMBL26101028 0.86 AURKB (0.47) PDGFRBKITRAF1BRAFAURKA
SCHEMBL26100134 0.84 KIT (0.46) PDGFRBKITRAF1BRAFKDR
SCHEMBL26100136 0.81 KIT (0.49) PDGFRBKITKDRHDAC3HDAC4
SCHEMBL29238333 0.78 KDR (0.49) PDGFRBKITRAF1BRAFAURKA
SCHEMBL30394615 0.78 KDR (0.49) PDGFRBKITRAF1BRAFAURKA
SCHEMBL30394611 0.76 KDR (0.54) PDGFRBKITRAF1BRAFAURKA
SCHEMBL29238215 0.76 KDR (0.54) PDGFRBKITRAF1BRAFAURKA
SCHEMBL26100883 0.75 KIT (0.51) PDGFRBKITAURKAKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB PDGFRB 3/4885KIT 2/4885RAF1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback